胶质母细胞瘤的恶性进展

Journal of Cell Science and Therapy Pub Date : 2014-09-29 DOI:10.4172/2157-7013.1000182

Y. Iwadate

{"title":"胶质母细胞瘤的恶性进展","authors":"Y. Iwadate","doi":"10.4172/2157-7013.1000182","DOIUrl":null,"url":null,"abstract":"Glioblastoma (GBM) is the most devastating type of human cancers with a median survival time ranging from 12-18 months following maximal therapies [1]. Glioma is classified into four malignancy grades according to histological features; the low-grade tumors including WHO Grade I (localized gliomas) and WHO Grade II (diffuse astrocytoma or oligodendrogliomas), and the high-grade tumors including WHO Grades III (anaplastic gliomas) and WHO Grade IV (GBM).","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"50 1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Malignant Progression of Glioblastoma\",\"authors\":\"Y. Iwadate\",\"doi\":\"10.4172/2157-7013.1000182\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glioblastoma (GBM) is the most devastating type of human cancers with a median survival time ranging from 12-18 months following maximal therapies [1]. Glioma is classified into four malignancy grades according to histological features; the low-grade tumors including WHO Grade I (localized gliomas) and WHO Grade II (diffuse astrocytoma or oligodendrogliomas), and the high-grade tumors including WHO Grades III (anaplastic gliomas) and WHO Grade IV (GBM).\",\"PeriodicalId\":150547,\"journal\":{\"name\":\"Journal of Cell Science and Therapy\",\"volume\":\"50 1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cell Science and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2157-7013.1000182\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cell Science and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2157-7013.1000182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

胶质母细胞瘤(GBM)是最具破坏性的人类癌症类型，最大治疗后的中位生存时间为12-18个月[1]。胶质瘤根据组织学特征可分为四个恶性级别;低级别肿瘤包括WHO一级(局限性胶质瘤)和WHO二级(弥漫性星形细胞瘤或少突胶质细胞瘤)，高级别肿瘤包括WHO三级(间变性胶质瘤)和WHO四级(GBM)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Malignant Progression of Glioblastoma

Glioblastoma (GBM) is the most devastating type of human cancers with a median survival time ranging from 12-18 months following maximal therapies [1]. Glioma is classified into four malignancy grades according to histological features; the low-grade tumors including WHO Grade I (localized gliomas) and WHO Grade II (diffuse astrocytoma or oligodendrogliomas), and the high-grade tumors including WHO Grades III (anaplastic gliomas) and WHO Grade IV (GBM).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cell Science and Therapy

自引率

0.00%

发文量